News | March 19, 2026
Strides acquires generic brands from Sandoz to boost Africa business
The initial consideration for the transaction is US$ 12 million
The initial consideration for the transaction is US$ 12 million
Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Subscribe To Our Newsletter & Stay Updated
